$ USD
¥ 人民币
$ USD
€ 欧元
English
简体中文
English
繁体中文
Sign In / Sign up
Home page
News
Tumor Information
Tumor Information
Tumor medication
Tumor medication
Drug data
Drug data
Tumor medication
Oncology
renal cell carcinoma
cell tumor
solid tumors
IDH1 mutation
non-small cell lung cancer
neurofibromatosis
liposarcoma
neurofibromatosis
Cachexia
bladder cancer
Common Medications
Common medications
Hematology
Hepatobiliary
chronic disease
Endocrinology
Rare disease drugs
Other medications
insomnia
depression
chronic cough
kidney transplant
Drug Classification
Brand Medicine Search
Brand Medicine Search
日本日医工株式会社
日本盐野义制药
日本杏林制药株式会社
日本株式会社
老挝卢修斯
hormone receptor positive
constipate
heart disease
constipate
depression
日本株式会社
日本田边三菱
英国FuturaMedical制药
日本盐野义制药
日本杏林制药株式会社
Medical Q&A
Medical Q&A
About Us
About Us
Menu
Home page
News
Tumor Information
Tumor Information
Tumor medication
Tumor medication
Drug data
Drug data
Tumor medication
Oncology
renal cell carcinoma
cell tumor
solid tumors
IDH1 mutation
non-small cell lung cancer
neurofibromatosis
liposarcoma
neurofibromatosis
Cachexia
bladder cancer
Common Medications
Common medications
Hematology
Hepatobiliary
chronic disease
Endocrinology
Rare disease drugs
Other medications
insomnia
depression
chronic cough
kidney transplant
Drug Classification
Brand Medicine Search
Brand Medicine Search
日本日医工株式会社
日本盐野义制药
日本杏林制药株式会社
日本株式会社
老挝卢修斯
hormone receptor positive
constipate
heart disease
constipate
depression
日本株式会社
日本田边三菱
英国FuturaMedical制药
日本盐野义制药
日本杏林制药株式会社
Medical Q&A
Medical Q&A
About Us
About Us
Home
Medical drugs
Medical drugs
Medical drugs-Medical Halo Global Pharmaceutical News_Targeted Drugs_New Anti-Cancer Drugs_Overseas Medical Information_【Medical Halo Global Pharmaceutical】
Spasentan/Sparsentan Efficacy and Potential Risks
2026-02-01 22:25:32
Check Details
Is spaxentan/sparsentan a new treatment for kidney disease?
2026-02-01 22:25:32
Check Details
Spaxentan/Sparsentan vs. Atrasentan: Comparison of Two Kidney Drugs
2026-02-01 22:25:32
Check Details
2025 spaxentan/sparsentan: drug introduction and market price
2026-02-01 22:25:32
Check Details
Spaxentan/sparsentan: new drug for the treatment of non-hormonal kidney disease
2026-02-01 22:25:32
Check Details
The Chinese name of Sparsentan is Sparsentan or Sparsentan
2026-02-01 22:25:32
Check Details
Is sparsentan/sparsentan an antihypertensive drug?
2026-02-01 22:25:32
Check Details
Spasentan/Sparsentan is a drug from which country?
2026-02-01 22:25:32
Check Details
What are sparsentan/sparsentan side effects
2026-02-01 22:25:32
Check Details
Reimbursement Policy for Sparsentan/Sparsentan
2026-02-01 22:25:32
Check Details
None
2026-02-01 22:25:32
Check Details
Ohtuvayre (Ensifentrine) - Can Ensifentrine Cure COPD?
2026-02-01 22:25:32
Check Details
1
2
...
1250
1251
1252
1253
1254
1255
1256
...
2441
2442
Category
Oncology
Hepatobiliary
dermatology
Endocrinology
Hematology
Andrology
Gynecology
Nephrology
Urology
Department of Infectious Diseases
Gastroenterology
Respiratory department
Neurology
Cardiology and Brain Department
ophthalmology
Psychiatry
Immunology Department
orthopedics
Burn Department
相关知识
1
Ganaxolone for CDKL5-Related Seizures: GABA-A Modulation, Not a Cure
2
Bepirovirsen for Chronic HBV Functional Cure: FDA Criteria and B-Well Data
3
Hovilpri (Pritelivir) Oral Anti-HSV: Immunocompromised Adults With Acyclovir-Refractory Mucocutaneous Lesions, 63% Healing at 28 Days
4
Juvmo (tavapadon) for Adult Parkinson’s: D1/D5 Partial Agonist, Once Daily, Monotherapy or Adjunct to Levodopa
5
Emcitate (tiratricol) for MCT8 Deficiency Peripheral Thyrotoxicosis: Bypass MCT8, Lower T3, Monitor Heart Rate and Bone
6
Lyrfigtu (lirafugratinib) for Pretreated FGFR2 Cholangiocarcinoma: 70mg Daily, REFOCUS Efficacy, Ocular and Phosphate Monitoring
7
Fayuvi (rebisufligene etisparvovec-hopf/UX111) for MPS IIIA: AAV9 SGSH Gene Therapy, Cognition, and Safety
8
Ramosetron Hydrochloride Orally Disintegrating Tablets: A 5-HT3 Receptor Antagonist for Diarrhea-Predominant IBS
9
Pixclara (Floretyrosine F-18/18F-FET) Glioma PET: Distinguishing Recurrence from Treatment-Related Change
10
Bexlutry (Lu-177 Dotatate) for SSTR-Positive GEP-NETs: PRRT Dosing and Safety Monitoring
11
Hibsago (Bepirovirsen) Japan Approval: CHB Functional Cure and B-Well Data Essentials
12
FDA Approves Isembyld (apitegromab-mstn), the World’s First Skeletal Muscle-Targeted Therapy for SMA